Trial Profile
A Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Assess the Efficacy and Safety of Clazosentan in Preventing Clinical Deterioration Due to Delayed Cerebral Ischemia (DCI), in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage (aSAH)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Clazosentan (Primary)
- Indications Cerebral vasospasm
- Focus Registrational; Therapeutic Use
- Acronyms REACT
- Sponsors Idorsia Pharmaceuticals
- 06 Feb 2023 According to an Idorsia Pharmaceuticals media release, the company will publish the data and interpretation in scientific literature in due course.
- 06 Feb 2023 Results published in the Idorsia Pharmaceuticals Media Release.
- 09 Jan 2023 According to an Idorsia Pharmaceuticals media release, Idorsia, will present at the 41st J.P. Morgan Healthcare Conference; presentation will cover discussion about eagerly anticipated Phase 3 REACT clinical results expected in the near-term